Roger Jeffs, the Chief Executive Officer of Liquidia Corp (NASDAQ: LQDA), has executed a sale of 75,000 shares of the company’s common stock. The total value of these transactions is approximately $3.07 million. These disposals were carried out over three consecutive trading days, spanning from May 5 to May 7, 2026.
The transactions were managed indirectly through Serendipity BioPharma LLC. Mr. Jeffs serves as a manager for this entity and maintains sole voting and dispositive power regarding the shares involved in these sales. To ensure regulatory compliance, the trades were executed under a pre-arranged Rule 10b5-1 trading plan, which Mr. Jeffs had originally adopted on November 5, 2025.
Detailed Transaction Breakdown
The sale was partitioned into three distinct daily tranches of 25,000 shares each:
- May 5, 2026: Mr. Jeffs sold 25,000 shares at a volume-weighted average price of $40.1037 per share. Individual transaction prices during this session ranged from $40.00 to $40.32.
- May 6, 2026: A second block of 25,000 shares was sold at an average price of $40.7829 per share, with the price range for these trades falling between $40.09 and $41.19.
- May 7, 2026: The final 25,000 shares were liquidated at an average price of $42.0854 per share, with individual prices oscillating between $41.05 and $42.87.
Following this period of selling, Mr. Jeffs maintains a significant position in the company. He directly holds 1,137,508 shares of Liquidia common stock, which includes various unvested restricted stock units. Furthermore, he holds an indirect interest of 46,595 shares through the Roger A. Jeffs Living Trust and an additional 1,348,095 shares via Serendipity BioPharma LLC.
Market Context and Financial Performance
The timing of these sales coincides with a period of notable growth for Liquidia Corp. The stock has recently traded near $42.28, representing a 172% return over the last year. This performance has helped drive the company’s market capitalization to $3.74 billion. While recent analysis suggests the stock may appear slightly undervalued at its current levels, the executive's divestment highlights active management of personal holdings.
Liquidia's recent financial reporting presents a nuanced picture. For the fourth quarter of 2025, the company reported revenue of $90.1 million, a figure that exceeded market expectations due to the successful launch of its Yutrepia drug. However, earnings per share for that same period did not meet projections, which has caused some concern among investors.
Despite these mixed quarterly results, several analysts have maintained or improved their outlooks based on the company's trajectory toward profitability and the strength of the Yutrepia launch. H.C. Wainwright raised its price target to $55, while BTIG increased its target to $50. BofA Securities has issued a Buy rating, citing Liquidia’s competitive position in the prostacyclin treatment market, and Raymond James reiterated a Strong Buy rating with a $47 target. Looking toward long-term growth, the company has provided revenue guidance exceeding $1 billion for the year 2027.